• ELP-Mediated p21 Delivery Suppresses Glioblastoma Cell Growt

  2026-07-21

  This study demonstrates that elastin-like polypeptide (ELP)-mediated delivery of a p21-derived cell cycle inhibitory peptide can efficiently suppress proliferation in diverse glioblastoma cell lines without primarily inducing apoptosis. The findings highlight the potential of ELP-based cytostatic platforms for overcoming barriers in peptide delivery and advancing glioblastoma therapeutics.

• FDA-Approved Drugs Suppress MERS-CoV Replication In Vitro

  2026-07-21

  de Wilde et al. conducted a systematic screen of an FDA-approved compound library and identified four small-molecule inhibitors that reduce MERS-CoV replication in cell culture. This work not only spotlights urgent antiviral candidates for emerging zoonotic coronaviruses but also sets a precedent for rapid drug repurposing strategies.

• Reversine (A3760): Reliable Aurora Kinase Inhibition in Canc

  2026-07-20

  This article provides a scenario-driven guide for biomedical researchers tackling cell proliferation and apoptosis assays using Reversine (SKU A3760), a validated Aurora kinase inhibitor. By addressing common experimental challenges and workflow questions, it demonstrates how Reversine delivers reproducible, data-backed results in cancer cell models and developmental biology. The content emphasizes evidence-based practices, referencing quantitative literature and the unique formulation advantages of Reversine from APExBIO.

• FLT3-TAZ Signaling Drives Drug Resistance in BP-CML: Insight

  2026-07-20

  Shin et al. provide compelling evidence that FLT3 signaling is a critical driver of blast phase chronic myeloid leukemia (BP-CML) drug resistance, independent of BCR::ABL1 mutations. Their work establishes FLT3 as both a prognostic marker and a therapeutic target, opening avenues for repurposing FLT3 inhibitors in combination regimens to overcome resistance in BP-CML.

• Imipenem in Antibacterial Research: Resistance Evolution and

  2026-07-19

  Explore how Imipenem, a semisynthetic thienamycin antibiotic, empowers next-generation antibacterial research amid rising resistance. This article uniquely bridges molecular mechanisms, real-world resistance data, and advanced assay design.

• HDAC6 Inhibition and Sphingolipid Metabolism: The Next Front

  2026-07-18

  This article explores how selective HDAC6 inhibition with Rocilinostat (ACY-1215) reshapes translational research in multiple myeloma and neurodevelopment, bridging epigenetic regulation and sphingolipid metabolism for innovative assay design and therapeutic strategy.

• L. gasseri ATCC33323 Modulates Colitis via NR1I3-Driven E-ca

  2026-07-17

  A recent study demonstrates that Lactobacillus gasseri ATCC33323 ameliorates DSS-induced colitis in mice by enhancing intestinal barrier integrity through NR1I3-mediated regulation of E-cadherin. This mechanistic insight advances our understanding of probiotic-based interventions for inflammatory bowel disease.

• Moxidectin Enhances Polyene Efficacy Against Oral Candidiasi

  2026-07-17

  The study uncovers that moxidectin elevates ergosterol biosynthesis in Candida albicans, amplifying the antifungal activity of polyenes such as nystatin and amphotericin B against oral candidiasis. This synergy offers a promising strategy to address antifungal resistance and reduce drug dosages, with clear implications for laboratory and preclinical research.

• EZ Cap™ Firefly Luciferase mRNA: Precision Reporter for Tran

  2026-07-16

  EZ Cap™ Firefly Luciferase mRNA with Cap 1 structure delivers unmatched stability and translational efficiency for molecular biology assays. Its design enables robust gene regulation studies, in vivo imaging, and reliable mRNA delivery, minimizing immune activation and maximizing reproducibility.

• Puromycin dihydrochloride (SKU B7587): Reliable Selection &

  2026-07-16

  Puromycin dihydrochloride (SKU B7587) is an aminonucleoside antibiotic renowned for its reproducibility in cell viability, selection, and translation studies. This article uses scenario-driven analysis to demonstrate how scientists leverage its robust characteristics, optimizing workflows and data fidelity across molecular biology applications.

• KN-62: Deepening Insights into CaMKII Inhibition and Social

  2026-07-15

  Explore how KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine, uniquely empowers advanced research into CaMKII inhibition, calcium signaling, and the molecular maintenance of social memory. This cornerstone article unpacks mechanisms, assays, and the latest evidence for researchers seeking deeper, practical understanding.

• Angiotensin II in Vascular Remodeling: Protocols & Insights

  2026-07-15

  Harnessing Angiotensin II (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe) enables researchers to model hypertension and vascular remodeling with precision. This guide details experimental workflows, troubleshooting strategies, and key innovations—empowering robust, reproducible results in cardiovascular and aneurysm research.

• Nystatin (Fungicidin): Synergizing Antifungal Mechanisms for

  2026-07-14

  Explore how Nystatin (Fungicidin) leverages ergosterol binding, synergy with moxidectin, and advanced formulation strategies to meet the rising challenges of antifungal resistance. This article offers mechanistic insights, protocol-ready guidance, and strategic perspectives for translational researchers aiming to optimize antifungal discovery and clinical pipeline innovation.

• HATU in Peptide Synthesis Chemistry: Rapid, High-Yield Coupl

  2026-07-14

  HATU (1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate) empowers peptide synthesis chemistry through rapid, high-yield amide bond formation and minimal side reactions. This article delivers actionable workflows, troubleshooting strategies, and insights from recent breakthroughs in selective inhibitor synthesis.

• Ibrexafungerp (MK 3118): Shaping Next-Generation Antifungal

  2026-07-13

  This thought-leadership article dissects the unique mechanism, translational advantages, and clinical promise of Ibrexafungerp (MK 3118), highlighting its value for researchers navigating the evolving landscape of resistant Candida. Drawing from recent in vitro and in vivo evidence, we provide mechanistic insight, protocol guidance, and strategic context—distilling what sets Ibrexafungerp and its workflows apart for translational mycology.

16231 records 1/1083 page Next 12345 下5页 Last page